<DOC>
	<DOCNO>NCT00976846</DOCNO>
	<brief_summary>The propose study seek determine appropriate balance removal undesirable small molecular substance ( urea , creatinine , phosphate ) large molecular substance ( ß2-m ) retention important substance ( e.g.albumin ) Baxter Xenium XPH dialyzer type define therapeutic condition olHDF primarily concern filtration flow rate relation blood flow/plasma water flow rate . Furthermore possibility removal certain protein-bound substance shall investigate together impact increase ultrafiltration parameter micro-inflammation .</brief_summary>
	<brief_title>Investigation Performance Compatibility Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration</brief_title>
	<detailed_description>The new high flux dialyser membrane Xenium XPH 210 Baxter show considerably increase removal ß2-Microglobulin olHDF post dilution mode together markedly increase removal small molecule ( urea , creatinine , phosphate ) . The loss albumin depend treatment modality . However , albumin permeability tolerable whole range total filtration rate select applied patient . Together albumin loss filtrate/dialysate small amount albuminbound substances detectable . Parameters micro-inflammation influence increase convective part treatment .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients sign informed consent form . Patients 18 75 year . Patients treat hemodialysis three month . Patients treat three time week 45 hour . Patients usually treat highflux dialyzer . Patients stable anticoagulation erythropoetin regimen . Patients whose hematocrit 28 % . Patients vascular access relate problem . Patients meet inclusion criterion . Patients poor nutritional status judge investigator . Patients gravid state . Patients unstable clinical condition ( e.g . cardiac vascular instability ) . Patients whose life expectancy le 12 month . Patients positive anamnesis first use syndrome . Patients known coagulation problem . Patients receive hemodialysis via single dialysis needle central venous catheter . Patients participate another study may interfere outcome present study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>line</keyword>
	<keyword>postdilution</keyword>
	<keyword>high-flux dialyzer</keyword>
	<keyword>hemodiafiltration</keyword>
</DOC>